Clinic
Sherrill Holdings, INC
Sherrill Holdings, INC was paid $1.39M by Medicaid between Dec 2018 and Dec 2024, across 50 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 75% of everything it billed.
33Billing provider infoSHERRILL HOLDINGS, INC
FORT PAYNE, AL 35967
FORT PAYNE, AL 35967
33aNPI1811460678assigned 01/04/2019
33bProvider typeClinic/Center
28Total paid$1.39M
24GClaims36,955
24DCodes billed50
24AFirst – last monthDec 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Alabama
Rank by total paid#14 of 57
Median peer was paid$94K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 71 | $2K | |
| 2019 | 4,012 | $102K | |
| 2020 | 4,270 | $182K | |
| 2021 | 7,335 | $352K | |
| 2022 | 6,966 | $291K | |
| 2023 | 8,104 | $265K | |
| 2024incomplete | 6,197 | $200K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 75% | 8,614 | 6,317 | $1.05M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.6% | 5,885 | 4,748 | $120K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.4% | 5,687 | 4,183 | $104K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 1,675 | 1,009 | $21K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.3% | 409 | 332 | $18K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.2% | 1,527 | 1,247 | $17K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.0% | 685 | 543 | $15K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 223 | 204 | $11K |
| 99460 | <1% | 179 | 160 | $10K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 29 | 27 | $6K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 157 | 129 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 514 | 395 | $4K |
38 more codes
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 165 | $2K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 39 | $2K |
| 99462 | <1% | 66 | $2K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 302 | $2K |
| 36416 | <1% | 634 | $1K | |
| 90700 | <1% | 182 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 139 | $936.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 24 | $566.93 |
| 99001 | <1% | 165 | $504.00 | |
| 90647 | <1% | 80 | $488.00 | |
| 90670 | <1% | 75 | $424.00 | |
| 90713 | <1% | 65 | $424.00 | |
| 99173 | <1% | 180 | $330.00 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 29 | $318.48 |
| 83655 | <1% | 15 | $210.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 144 | $189.66 |
| 92552 | <1% | 15 | $154.00 | |
| 87807 | <1% | 13 | $134.10 | |
| 90686 | <1% | 19 | $110.06 | |
| 85018 | <1% | 177 | $48.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 33 | $42.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 22 | $30.86 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 111 | $26.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 132 | $21.98 |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 96 | $0.38 |
| 3078F | 0% | 1,352 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 26 | $0.00 |
| 87652 | 0% | 164 | $0.00 | |
| 3008F | 0% | 3,702 | $0.00 | |
| 3044F | 0% | 436 | $0.00 | |
| 3079F | 0% | 364 | $0.00 | |
| 3074F | 0% | 1,674 | $0.00 | |
| G2025 | Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only | 0% | 258 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 88 | $0.00 |
| Q3014 | Telehealth originating site facility fee | 0% | 218 | $0.00 |
| 94761 | 0% | 104 | $0.00 | |
| 87650 | 0% | 35 | $0.00 | |
| 96112 | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWESTFALL, LISA (ADMINISTRATOR)
Parent organizationSHERRILL HOLDINGS, INC